Señales en vivo de OGEN | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 15:11):

Stats
Volumen de hoy	9 431.00
Volumen promedio	91 704.00
Capitalización de mercado	4.71M
EPS	$0 ( 2024-04-17 )
Próxima fecha de ganancias	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.230
ATR14	$0.00900 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-31	Koski Robert C	Buy	0
2023-12-28	Redmond J Michael	Buy	75 000	Employee Option (Right to Buy)
2023-12-28	Redmond J Michael	Buy	0
2023-11-30	Telling Fred	Sell	3 500	Common Stock
2023-10-04	Gandolfo John P	Buy	5 102	Non-Employee Director Option (Right to Buy)

INSIDER POWER
43.98
Last 90 transactions
Buy: 9 608 650 \| Sell: 19 845 876

Oragenics Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oragenics Inc Finanzas

Annual	2023
Ingresos:	$37 653.00
Beneficio Bruto:	$10 262.00 (27.25 %)
EPS:	$-9.18

FY	2023
Ingresos:	$37 653.00
Beneficio Bruto:	$10 262.00 (27.25 %)
EPS:	$-9.18

FY	2022
Ingresos:	$131 521
Beneficio Bruto:	$86 854.00 (66.04 %)
EPS:	$-7.05

FY	2021
Ingresos:	$86 987.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.00232

Financial Reports:

No articles found.

Oragenics Inc

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.